Claudio HoldCo A/S - CVR: 38204424

2021, DKK

29.06.2022

Bruttoresultat

0

Primær drift

-127'

Årets resultat

92.965'

Aktiver

1.093''

Kortfristede aktiver

18.400'

Egenkapital

1.093''

Afkastningsgrad

-0 %

Soliditetsgrad

100 %

Likviditetsgrad

+500%

Resultat

29.06.2022

Årsrapport	2021 29.06.2022	2020 14.04.2021	2019 20.04.2020	2018 16.05.2019	2016 23.03.2018
Nettoomsætning	0	0	0	0	0
Bruttoresultat	0	0	0	0	0
Resultat af primær drift	-127.000	-202.000	-270.000	-52.000	-158.000
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0
Finansielle indtægter	436.000	629.000	0	0	0
Finansieringsomkostninger	1.000	-6.000	-2.000	-2.000	-48.000
Andre finansielle omkostninger	0	0	0	0	0
Resultat før skat	-92.897.000	17.572.000	-57.843.000	-101.219.000	-34.878.000
Resultat	92.965.000	17.481.000	-57.784.000	-101.207.000	-34.838.000
Forslag til udbytte	0	0	0	0	0

Aktiver

29.06.2022

Årsrapport	2021 29.06.2022	2020 14.04.2021	2019 20.04.2020	2018 16.05.2019	2016 23.03.2018
Kortfristede varebeholdninger	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	18.342.000	18.191.000	18.519.000	16.067.000	44.902.000
Likvider	58.000	16.000	21.000	67.000	0
Kortfristede aktiver	18.400.000	18.207.000	18.540.000	16.134.000	44.902.000
Immaterielle aktiver og goodwill	0	0	0	0	0
Finansielle anlægsaktiver	1.074.331.000	1.163.904.000	1.149.531.000	1.204.404.000	1.220.990.000
Materielle aktiver	0	0	0	0	0
Langfristede aktiver	1.074.331.000	1.163.904.000	1.149.531.000	1.204.404.000	1.220.990.000
Aktiver	1.092.731.000	1.182.111.000	1.168.071.000	1.220.538.000	1.265.892.000

Aktiver

29.06.2022

Passiver

29.06.2022

Årsrapport	2021 29.06.2022	2020 14.04.2021	2019 20.04.2020	2018 16.05.2019	2016 23.03.2018
Forslag til udbytte	0	0	0	0	0
Egenkapital	1.092.634.000	1.181.963.000	1.167.936.000	1.220.132.000	1.239.099.000
Hensatte forpligtelser	0	0	2.000	0	0
Langfristet gæld til banker	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0
Leverandører af varer og tjenesteydelser	29.000	53.000	133.000	0	0
Kortfristede forpligtelser	97.000	148.000	133.000	406.000	26.793.000
Gældsforpligtelser	97.000	148.000	133.000	406.000	26.793.000
Forpligtelser	97.000	148.000	133.000	406.000	26.793.000
Passiver	1.092.731.000	1.182.111.000	1.168.071.000	1.220.538.000	1.265.892.000

Passiver

29.06.2022

Nøgletal

29.06.2022

Årsrapport	2021 29.06.2022	2020 14.04.2021	2019 20.04.2020	2018 16.05.2019	2016 23.03.2018
Afkastningsgrad	0,0 %	0,0 %	0,0 %	0,0 %	0,0 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	8,5 %	1,5 %	-4,9 %	-8,3 %	-2,8 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	12.700,0 %	-3.366,7 %	-13.500,0 %	-2.600,0 %	-329,2 %
Soliditestgrad	100,0 %	100,0 %	100,0 %	100,0 %	97,9 %
Likviditetsgrad	18.969,1 %	12.302,0 %	13.939,8 %	3.973,9 %	167,6 %

Resultat

29.06.2022

Gæld

29.06.2022

Årsrapport

29.06.2022

Nyeste:01.01.2021- 31.12.2021(offentliggjort: 29.06.2022)

Beretning

29.06.2022

Dato for ledelsens godkendelse af årsrapporten:2022-05-27

Ledelsespåtegning:Statement by Management on the annual report

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Claudio HoldCo A/S for the financial year 1 January - 31 December 2021.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business ActivitiesClaudio Holdco A/S (“the Group”) was founded in 2017 with the purpose of investing in the fully owned subsidiary Claudio Bidco A/S, parent company for the subsidiaries Fertin Pharma A/S, NordicCan A/S and NCP NextGen A/S. The Group is a specialist Contract Development and Manufacturing Organization (“CDMO”) offering innovative, high-quality pharmaceutical and nutraceutical products for oral and intra-oral delivery. The Group’s current main product formats (“delivery systems”) are chewing gum, lozenges, powders, fast dissolvable tablets, Zapliq® chewables, and Zapliq® chewing gum. The Group is the world’s largest independent developer and manufacturer of medicated chewing gum and has over recent years expanded into other specialized solid dosage oral and intra-oral delivery systems. The Group strives to develop innovative oral and intra-oral delivery systems that offer convenient and pleasurable delivery of active pharmaceutical ingredients (“APIs") and nutraceutical ingredients (“AIs") to patients and consumers. In 2021, the largest category continues to be high-quality chewing gum and lozenges systems applied within Nicotine Replacement Therapy (“NRT”) category. Following the current diversification strategy, the Group is still utilizing its highly flexible delivery systems to grow business outside the NRT category, applying a wider range og APIs and AIs for OTC pharma and nutraceutical categories. During 2021, execution of the strategy has been materially impacted by the COVID-19 pandemic, which has caused delays in customer’s plans to bring new products to market. The Group is headquartered in Vejle, Denmark, where it owns and operates US FDA and EU GMP approved R&D and manufacturing facilities. Furthermore, the Group owns and operates commercial, R&D and manufacturing facilities in India and Canada. The ultimate ownership of the Group has changed as of 15 September 2021, as Philip Morris International acquired full ownership from the previous owners EQT Mid-Market Europe and the Bagger-Sørensen family.